A US district court has dismissed a petition by Israel's Taro Pharmaceutical Industries to block leading Indian drug maker Sun Pharma from launching an open offer to acquire majority stake in the former.
In a filing to the Bombay Stock Exchange, Sun Pharma said the US Federal Trade Commission (FTC) has granted early termination of the anti-trust waiting period for the previously announced tender offer by its subsidiary Alkaloida Chemical Company Exclusive Group Ltd. Last month the Mumbai-based firm had launched an open offer at a price of $7.75 per share to acquire all outstanding shares of Taro, including all of the founders' shares.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances